This is the authors' abstract. We don't add key points for this paper.
In a working group of the National Institutes of Health focusing on biomarkers and surrogate end-points, a biomarker was defined as a “characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [1]. In the same document, the National Institutes of Health defined a clinical end-point as “a characteristic or variable that reflects how a patient feels, functions, or survives” and a surrogate end-point as a “biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence” [1]. Biomarkers accurately assessing disease activity and response to therapy are needed to develop better COPD treatment
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
David M. Mannino (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: